Cellectar Biosciences is an emerging biopharmaceutical company with the intellectual curiosity and drive to challenge existing norms to deliver meaningful therapies to cancer patients utilizing a proprietary PLE platform targeting modality. Our lead asset, Iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. We believe this profile differentiates Iopofosine from many traditional on-market treatments. Iopofosine is currently being evaluated in a pivotal study for Waldenstrom’s macroglobulinemia in our CLOVER-WaM study, as well as the multi cohort CLOVER-1 Phase 2 study in adult B-cell malignancies and the CLOVER-2 Phase 1 study in a variety of refractory pediatric cancers. Visit us at www.Cellectar.com to learn more.